Biotechnology - Mergers & Acquisitions, Research


Popular Filters

1 to 25 of 30 results

MorphoSys gets milestone from Novartis; acquires new technology


German company MorphoSys says it has received a milestone payment from Novartis in connection with the…

BiotechnologyLanthio PharmalanthipeptideMergers & AcquisitionsMorphoSysNovartisOphthalmicsResearch

Biotie passes up on option to acquire Neurelis

Biotie passes up on option to acquire Neurelis


Finland-based biotech firm Biotie Therapies said on Friday that it has decided not to exercise its exclusive…

Acute repetitive seizuresBiotechnologyBiotie TherapiesDiazepamFinlandHepatologyMergers & AcquisitionsNeurelisNeurologicalNRL-1Pediatric and adult epilepsyPharmaceuticalResearchtozadenant

Roche invests in Stratos Genomics for “Sequencing by Expansion”

Roche invests in Stratos Genomics for “Sequencing by Expansion”


Swiss pharma major Roche has made a strategic investment in USA-based Stratos Genomics and entered into…

BiotechnologyMergers & AcquisitionsResearchRocheStratos Genomics

NeoStem to acquire California Stem Cell, expanding pipeline


USA-based NeoStem has entered into a definitive agreement to acquire California Stem Cell, an Irvine,…

BiotechnologyCalifornia Stem Cellmelapuldencel-TMergers & AcquisitionsNeoStemOncologyResearch

Second collaboration between FORMA Therapeutics and Celgene


Privately-held drug discovery firm FORMA Therapeutics has entered a second strategic collaboration and…

BiotechnologyCelgeneFORMA TherapeuticsLicensingMergers & AcquisitionsResearch

Ohr Pharma and Cold Spring Harbor Lab set up JV to develop trodusquemine


US biotech firm Ohr Pharmaceutical and not-for-profit cancer research center Cold Spring Harbor Laboratory…

BiotechnologyDepYmedMergers & AcquisitionsOhr PharmaceuticalResearchtrodusquemine

Genzyme to gain rights to certain Alnylam rare disease pipeline products

Genzyme to gain rights to certain Alnylam rare disease pipeline products


French drug major Sanofi’s US biotech subsidiary Genzyme and Alnylam Pharmaceuticals have significantly…

Alnylam PharmaceuticalsBiotechnologyGenzymeLicensingMergers & AcquisitionspatisiranRare diseasesResearchSanofi

OncoMed rockets on possible multi-billion dollar deal with Celgene

OncoMed rockets on possible multi-billion dollar deal with Celgene


US biotech companies OncoMed Pharmaceuticals and Celgene have entered an agreement to jointly develop…

Anti-DLL4BiotechnologyCelgenedemcizumabLicensingMergers & AcquisitionsOMP-21M18OncologyOncoMed PharmaceuticalsResearch

Merck KGaA eighth EPP spin-off to focus on infertility treatment

Merck KGaA eighth EPP spin-off to focus on infertility treatment


USA-based EMD Serono, one of German drug and chemical group Merck KGaA’s biotechnology subsidiaries,…

BiotechnologyEMD SeronoMerck KGaAMerck SeronoMergers & AcquisitionsReproductiveResearchTocopheRx

Aphios spins off Amylon to develop novel Alzheimer’s disease drug


US clinical-stage biotech firm Aphios says it has spun-off a subsidiary, Amylon, to finance, develop…

AmylonAPH-1104AphiosBiotechnologyFinancialMergers & AcquisitionsNeurologicalResearch

PharmAkea, Celgene and Bay City Capital collaborate on cancer and fibrotic disease

PharmAkea, Celgene and Bay City Capital collaborate on cancer and fibrotic disease


PharmAkea Therapeutics and Bay City Capital have entered a strategic collaboration with Celgene designed…

BiotechnologyCelgeneMergers & AcquisitionsNorth AmericaOncologyPharmAkeaResearch

Biotech industry has "implementation gap" around demonstrating the value of products under development


Ernst & Young's annual biotech report shows strong performance by major players but a challenging environment…

BiotechnologyEuropeFinancialMergers & AcquisitionsNorth AmericaResearch

Ligand acquires financial rights to over 15 development programs from Selexis


US drugmaker Ligand Pharmaceuticals (Nasdaq: LGND) has acquired a portfolio of potential future milestone…

BiotechnologyLigand PharmaceuticalsMergers & AcquisitionsResearchSelexis

AstraZeneca acquires AlphaCore; Merck Serono links with BioMed X


In line with its stated policy of targeted acquisitions, Anglo-Swedish drug major AstraZeneca (LSE: AZN)…

AlphaCore PharmaAstraZenecaBiotechnologyCardio-vascularMerck KGaAMerck SeronoMergers & AcquisitionsMetabolicsPharmaceuticalResearch

News briefs from Alimera on Iluvien and Xencor on Xtend; Galapagos milestone and acquisition


US biopharma company Alimera Sciences (Nasdaq: ALIM) says that the Spanish Agency of Drugs and Medical…

Alimera SciencesBiotechnologyCangenixGalapagosIluvienJanssenJohnson & JohnsonMergers & AcquisitionsOphthalmicsPharmaceuticalRegulationResearchXencorXtend

Almirall expands in personalized medicine with 5% equity stake in AB-Biotics


Spain's largest pharma company Almirall (ALM.MC) says it has reached an agreement with the Spanish biotech…

AB-BioticsAlmirallBiotechnologyMergers & AcquisitionsPharmaceuticalResearch

Celgene in deal with PharmAria, including an acquisition option


Recently-formed drug discovery company PharmAria has entered into an agreement with US biotech firm Celgene…

BiotechnologyCelgeneMergers & AcquisitionsOncologyPharmAriaResearch

Achillion Pharma moves up as a contender in the HCV market, GlobalData believes


On September 27, Achillion Pharmaceuticals (Nasdaq: ACHN) released news of positive results surrounding…

ACH-3102Achillion PharmaceuticalsAnti-viralsBiotechnologyMergers & AcquisitionsPharmaceuticalResearch

Russia's Maxwell Biotech Venture Fund invests in Osteros Biomedica


Earlier this month, the investment committee of Maxwell Biotech Venture Fund (MBVF), founded with the…

BiotechnologyMaxwell BiotechMBC PharmaMBC-11Mergers & AcquisitionsOncologyOsteros BiomedicaResearch

Compugen and Merck Serono set up biomarker company Neviah Genomics


German drug major Merck KGaA's (MRK: DE) Merck Serono division and Israel-based Compugen (Nasdaq: CGEN)…

BiotechnologyCompugenMerck KGaAMerck SeronoMergers & AcquisitionsResearch

Pharming considers options, including a sale of the company


Netherland-based biotech company Pharming Group (NYSE Euronext: PHARM) yesterday revealed that it is…

BiotechnologyLicensingMergers & AcquisitionsPharmingRare diseasesResearchRuconest

1 to 25 of 30 results

Back to top